FDA approves first-of-its-kind pill for advanced pancreatic cancer six months early

FDA approves daraxonrasib, the first targeted pill for advanced pancreatic cancer, offering patients longer survival and fewer side effects.

The post FDA approves first-of-its-kind pill for advanced pancreatic cancer six months early appeared first on The American Bazaar.